Department of Radiation Oncology, Celal Bayar University Medical School, Manisa, Turkey.
Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):433-9. doi: 10.1016/j.ijrobp.2009.02.010. Epub 2009 Apr 20.
This study reports the long term outcomes of postoperative radiotherapy in patients with resection for non-small-cell lung cancer (NSCLC).
A total of 98 patients with resected NSCLC who received postoperative radiotherapy (PORT) between January 1994 and December 2004 were retrospectively analyzed. The most frequently performed surgical procedure was lobectomy (59 patients), followed by pneumonectomy (25), wedge resection (8), and bilobectomy (6). Postoperative radiotherapy was delivered as an adjuvant treatment in 71 patients, after a wedge resection in 8 patients, and after an R1 resection in 19 patients. The PORT was administered using a Co-60 source in 86 patients and 6-MV photons in 12 patients. A Kaplan-Meier estimate of overall survival, locoregional control, and distant metastasis-free survival were calculated.
Stages included I (n =13), II (n = 50), IIIA (n = 29), and IIIB (n = 6). After a median follow-up of 52 months median survival was 61 months. The 5-year overall survival, locoregional control, and distant metastasis-free survival rates for the whole group were 50%, 78%, and 55% respectively. The RT dose, Karnofsky performance status, age, lateralization of the tumor, and pneumonectomy were independent prognostic factors for OAS; anemia and the number of involved lymph nodes were independent prognostic factors for LC.
Doses of PORT of greater than 54 Gy were associated with higher death rate in patients with left-sided tumor, which may indicate a risk of radiation-induced cardiac mortality.
本研究报告了非小细胞肺癌(NSCLC)患者手术后放疗的长期结果。
回顾性分析了 1994 年 1 月至 2004 年 12 月期间接受术后放疗(PORT)的 98 例 NSCLC 患者。最常进行的手术是肺叶切除术(59 例),其次是全肺切除术(25 例)、楔形切除术(8 例)和双肺叶切除术(6 例)。71 例患者接受术后辅助放疗,8 例患者接受楔形切除术,19 例患者接受 R1 切除术。86 例患者采用 Co-60 源放疗,12 例患者采用 6-MV 光子放疗。采用 Kaplan-Meier 法计算总生存、局部区域控制和无远处转移生存。
分期包括 I 期(n=13)、II 期(n=50)、IIIA 期(n=29)和 IIIB 期(n=6)。中位随访 52 个月后,中位生存期为 61 个月。全组 5 年总生存率、局部区域控制率和无远处转移生存率分别为 50%、78%和 55%。RT 剂量、卡诺夫斯基表现状态、年龄、肿瘤侧化和全肺切除术是 OAS 的独立预后因素;贫血和受累淋巴结数是 LC 的独立预后因素。
左侧肿瘤患者 PORT 剂量大于 54 Gy 与死亡率升高相关,这可能表明存在放射诱导的心脏死亡率风险。